OncoTherapy Science Inc.

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

9 documents for OncoTherapy Science Inc.

- Research and Markets: Kidney Cancer - Pipeline Review, H1 2012.
...* Amgen Inc., H1 2012. * AstraZeneca PLC, H1 2012. * Eli Lilly...* Light Sciences Oncology, Inc., H1 2012. * Novartis AG, H1 2012. *...* MOLOGEN AG, H1 2012. * OncoTherapy Science, Inc., H1 2012. * Threshold Pharmaceutical...
- Business Wire
- March 06, 2012
- Nanobiotechnology, synthetic biology, and RNAi: patent portfolios for maximal near-term commercialization and commons for maximal long-term medical gain.
...The Present and Near Future: Incremental Progress B. In 20-to-40 Years: Revolutionary Progr... Value When the Pertinent Patent Law, Science, and Technology are All Uncertain and Quickly Chan... potential of targeting mutations in oncotherapy. Compare Lawrence A. Loeb et al., Point-Counterpoi...
- Marquette Intellectual Property Law Review
- Vol. 13 Nbr. 1, January 2009
- Research and Markets: In-depth Data on Bile Duct Cancer Global Clinical Trials Market, Provided in New Review.
...It includes an overview of the trial numbers and their recruit...* AstraZeneca PLC. * OncoTherapy Science, Inc. * OSI Pharmaceuticals, Inc. * Eli Li...
- Business Wire
- March 14, 2011

- Research and Markets: Bladder Cancer Therapeutics - Global Strategic Business Report.
.... The report profiles 56 companies including many key and niche players worldwide such as: . * .... * Bioniche Life Sciences Inc. . * Bristol-Myers Squibb Company . * Celldex ...* Oncogenex Pharmaceuticals Inc. . * OncoTherapy Science Inc. . * Sanofi-Aventis . * Spectrum Pharm...
- Business Wire
- March 11, 2010
- Research and Markets: New Report Analyzes Operations and Prospects at Diversified Company Kyowa Hakko.
... pharmaceutical products has placed an increasing emphasis on R&D. . EXECUTIVE SUMMARY Introduction ... Pharma Corporation NovaCardia Inc OncoTherapy Science Inc Orexo Pharmaceuticals AB Sekisuki Chem...
- Business Wire
- April 25, 2007
- Research and Markets: Kyowa Hakko Pharmaceutical Company Financial Performance and its Company Strategy.
...Index of Charts . Companies Mentioned Include: . --Astellas Pharma Inc . --Biogen Idec Inc . --B...--NovaCardia Inc . --OncoTherapy Science Inc (OTS) . --Orexo Pharmaceuticals AB . -...
- Business Wire
- May 25, 2006
- Which Diseases Will RNAi Drugs be Used to Treat and What Barriers Will RNAi Drugs Need to Overcome.
... of how the technology will evolve, including nearly unpopulated "white-space". . It also contai.... --Nektar . --Novartis . --Oncotherapy Science . --Origene_Tech . --Pfizer . --Quiagen . ...
- Business Wire
- July 25, 2006
- Morphotek CEO Named Ernst & Young Entrepreneur Of The Year(R) 2007 Award Winner in Greater Philadelphia Region.
... for Entrepreneurial Excellence in Life Sciences . EXTON, Pa. -- Nicholas C. Nicolaides, Ph.D., pre... and chief executive officer of Morphotek, Inc., a U.S. subsidiary of Eisai Co., Ltd., was awarde...; and integrative oncology including oncotherapy and supportive-care treatments. Through a global n...
- Business Wire
- June 26, 2007
- Morphotek Receives $2.3M in Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies Against Biowarfare Agents.
...EXTON, Pa. -- Morphotek, Inc., a subsidiary of Eisai Co., Ltd. announced today ... for Infectious Diseases (USAMRIID), a Science and Technology Laboratory of the U.S. Army at Fort...; and integrative oncology including oncotherapy and supportive-care treatments. Through a global n...
- Business Wire
- September 19, 2007